Pediatric blood & cancer
-
Pediatric blood & cancer · Aug 2009
Case ReportsLactic acidosis and hypoglycemia with ALL relapse following engrafted bone marrow transplant.
Lactic acidosis together with hypoglycemia in the face of hematologic malignancy is a grave development. A 7-year-old male with pre-B-cell ALL following hematopoietic cell transplant was admitted to our hospital in his second relapse. ⋯ Care was withdrawn on hospital day 9. Further understanding of the mechanisms that cause the combined onset of lactic acidosis and hypoglycemia will help clinicians in implementing timely therapies that may reduce mortality.
-
Pediatric blood & cancer · Aug 2009
Dissatisfaction with hospital care for children with sickle cell disease not due only to race and chronic disease.
A previous study reported increased dissatisfaction with hospital care for children with sickle cell disease (SCD); however, its small size excluded determining whether race and chronic disease explained the difference. ⋯ Parents of children with SCD report increased dissatisfaction with care. While dissatisfaction was higher in minority families, the high rate of parental concern about race as a reason for families of children with SCD is not seen in African-American families of children with asthma.
-
Pediatric blood & cancer · Jul 2009
Case ReportsSialoblastoma and hepatoblastoma in a newborn infant.
We report a case of a newborn infant who had simultaneous sialoblastoma and hepatoblastoma tumours at birth. The diagnoses were made on post mortem examination. Both of these are rare tumours in the neonatal period.
-
Pediatric blood & cancer · Jul 2009
Multicenter StudyVariation in receipt of opioids by pediatric oncology patients who died in children's hospitals.
Opioids are a cornerstone of palliation of pain. We sought to assess variation in opioid prescription during the last week of life among a cohort of pediatric oncology patients who died while hospitalized. ⋯ Opioid prescription during the hospitalized portion of the last week of life varies substantially among hospitals, even after adjustment for clinical characteristics of the patients. The reasons for this significant variation, especially the component explained by hospital-level and not patient-level factors, warrant more scrutiny.
-
Pediatric blood & cancer · Jul 2009
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Sunitinib inhibits KIT and other members of the split-kinase-domain family of receptor tyrosine kinases. Sunitinib prolongs survival in adult patients with imatinib-resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib. ⋯ Sunitinib treatment was associated with substantial initial antitumor activity and acceptable tolerability in this group of pediatric patients with imatinib-resistant GIST.